Abstract
Conditioned place aversion in rats has face validity as a measure of the aversive stimulus effects of opiate withdrawal that reflects an important motivational component of opiate dependence. The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of opiate withdrawal. Male Sprague–Dawley rats were implanted with two subcutaneous morphine pellets and 5 days later began place conditioning training following subcutaneous administration of a low dose of naloxone. Animals were subjected to three pairings of a low dose of naloxone (15 μg/kg, s.c.) to one arm of a three-chambered place conditioning apparatus. Buprenorphine administered prior to each pairing dose-dependently blocked the place aversion produced by precipitated opiate withdrawal. A corticotropin-releasing factor-1 (CRF1) receptor antagonist (antalarmin) also reversed the place aversion produced by precipitated opiate withdrawal. Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats. No effect was observed with pretreatment of the dopamine partial agonist terguride or the selective serotonin reuptake inhibitor fluoxetine. Also, chronic pretreatment with acamprosate (a glutamate receptor modulator used to prevent relapse in alcohol dependence) did not alter naloxone-induced place aversion. Buprenorphine by itself in dependent rats produced a mild place preference at low doses and a mild place aversion at higher doses. These results suggest that buprenorphine blocks the aversive stimulus effects of precipitated opiate withdrawal in rats and provides some validity for the use of place conditioning as a measure that is sensitive to potential opiate-dependence medications. In addition, these results suggest that CRF1 antagonists can block the aversive stimulus effects of opiate withdrawal and may be potential therapeutic targets for opiate dependence.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
al Qatari M, Bouchenafa O, Littleton J (1998). Mechanism of action of acamprosate: Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 22: 810–814.
Baldwin HA, Koob GF (1993). Rapid induction of conditioned opiate withdrawal in the rat. Neuropsychopharmacology 8: 15–21.
Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chretien P et al (1984). A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 21: 787–789.
Cador M, Ahmed SH, Koob GF, Le Moal M, Stinus L (1992). Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res 597: 304–309.
Cole JC, Littleton JM, Little HJ (2000). Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology 147: 403–411.
Cowan A (1992). Buprenorphine and gastrointestinal transit in rats: effect of naloxone on the biphasic dose–response curve. Clin Exp Pharmacol Physiol 19: 47–49.
Cowan A, Lewis JW, Macfarlane IR (1977). Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60: 537–545.
Cummings S, Elde R, Ells J, Lindall A (1983). Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study. J Neurosci 3: 1355–1368.
Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P et al (1998). Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 82: 107–114.
Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF et al (1999). The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140: 79–86.
Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000). Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403: 430–434.
Frenois F, Cador M, Caille S, Stinus L, Le Moine C (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377–1389.
Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P (1991). Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 26: 129–137.
Gold LH, Stinus L, Inturrisi CE, Koob GF (1994). Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol 253: 45–51.
Gracy KN, Dankiewicz LA, Koob GF (2001). Opiate withdrawal-induced Fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology 24: 152–160.
Hand TH, Koob GF, Stinus L, Le Moal M (1988). Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. Brain Res 474: 364–368.
Heinrichs SC, Britton KT, Koob GF (1991). Both conditioned taste preference and aversion induced by corticotropin-releasing factor. Pharmacol Biochem Behav 40: 717–721.
Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995). Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6: 74–80.
Heyser CJ, Schulteis G, Durbin P, Koob GF (1998). Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 18: 125–133.
Holter SM, Landgraf R, Zieglgansberger W, Spanagel R (1997). Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Alcohol Clin Exp Res 21: 862–868.
Jasinski DR, Pevnick JS, Griffith JD (1978). Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35: 501–516.
Johnson RE, McCagh JC (2000). Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2: 519–526.
Koob GF (1999). Corticotropin-releasing factor, norepinephrine and stress. Biol Psychiatry 46: 1167–1180.
Koob GF, Heinrichs SC (1999). A role for corticotropin-releasing factor and urocortin in behavioral responses to stressors. Brain Res 848: 141–152.
Koob GF, Heinrichs SC, Menzaghi F, Pich EM, Britton KT (1994). Corticotropin releasing factor, stress and behavior. Semin Neurosci 6: 221–229.
Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52–58.
Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97–129.
Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR (2002). Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 26: 586–592.
Koob GF, Pettit HO, Ettenberg A, Bloom FE (1984). Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. J Pharmacol Exp Ther 229: 481–486.
Koob GF, Sanna PP, Bloom FE (1998). Neuroscience of addiction. Neuron 21: 467–476.
Le Magnen J, Tran G, Durlach J, Martin C (1987). Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 4: 97–102.
Lee Y, Schulkin J, Davis M (1994). Effect of corticosterone on the enhancement of the acoustic startle reflex by corticotropin releasing factor (CRF). Brain Res 666: 93–98.
Lizasoain I, Leza JC, Lorenzo P (1991). Buprenorphine: bell-shaped dose–response curve for its antagonist effects. Gen Pharmacol 22: 297–300.
Lu L, Ceng X, Huang M (2000a). Corticotropin-releasing factor receptor type I mediates stress-induced relapse to opiate dependence in rats. NeuroReport 11: 2373–2378.
Lu L, Liu D, Ceng X, Ma L (2000b). Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12: 4398–4404.
Lu L, Liu Z, Huang M, Zhang Z (2003). Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 84: 1378–1386.
Lukas SE, Griffiths RR, Brady JV (1983). Buprenorphine self-administration by the baboon: comparison with other opioids. In: Harris LS (eds). Problems of Drug Dependence 1982: Proceedings of the 44th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. (series title: NIDA Research Monograph, Vol. 43). National Institute on Drug Abuse: Rockville MD. pp 178–183.
Macey DJ, Koob GF, Markou A (2000). CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res 866: 82–91.
Mason BJ (2001). Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 62(Suppl 20): 42–48.
Mas-Serrano P, Granero L, Martin-Algarra RV, Guerri C, Polache A (2000). Kinetic study of acamprosate absorption in rat small intestine. Alcohol Alcohol 35: 324–330.
Mello NK, Bree MP, Mendelson JH (1981). Buprenorphine self-administration by rhesus monkey. Pharmacol Biochem Behav 15: 215–225.
Merlo-Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF et al (1995). Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439–5447.
Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M (1998). Mechanism of action of acamprosate: Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 22: 802–809.
Orsini C, Koob GF, Pulvirenti L (2001). Dopamine partial agonist reverses amphetamine withdrawal in rats. Neuropsychopharmacology 25: 789–792.
Pascucci T, Cioli I, Pisetzky F, Dupre S, Spirito A, Nencini P (1999). Acamprosate does not antagonise the discriminative stimulus properties of amphetamine and morphine in rats. Pharmacol Res 40: 333–338.
Porrino LJ, Ritz MC, Goodman NL, Sharpe LG, Kuhar MJ, Goldberg SR (1989). Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci 45: 1529–1535.
Pulvirenti L, Balducci C, Piercy M, Koob GF (1998). Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 286: 1231–1238.
Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993). Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605: 25–32.
Richter RM, Weiss F (1999). In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32: 254–261.
Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050–2054.
Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995). Brain corticotropin-releasing factor mediates ‘anxiety-like’ behavior induced by cocaine withdrawal in rats. Brain Res 675: 89–97.
Schulkin J, McEwen BS, Gold PW (1994). Allostasis, amygdala, and anticipatory angst. Neurosci Biobehav Rev 18: 385–396.
Schulteis G, Ahmed SH, Morse AC, Koob GF, Everitt BJ (2000). Conditioning and opiate withdrawal: the amygdala links neutral stimuli with the agony of overcoming drug addiction. Nature 405: 1013–1014.
Schulteis G, Gold LH, Koob GF (1997). Preclinical behavioral models for addressing unmet needs in opiate addiction. Semin Neurosci 9: 94–109.
Schulteis G, Markou A, Gold LH, Stinus L, Koob GF (1994). Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose–response analysis. J Pharmacol Exp Ther 271: 1391–1398.
Shaham Y, Erb S, Leung S, Buczek Y, Stewart J (1998). CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 137: 184–190.
Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J (1997). Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17: 2605–2614.
Shepard JD, Barron KW, Myers DA (2000). Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res 861: 288–295.
Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgänsberger W (1996a). Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305: 39–44.
Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W (1996b). Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 305: 45–50.
Spanagel R, Sillaber I, Zieglgansberger W, Corrigall WA, Stewart J, Shaham Y (1998). Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology 139: 391–401.
Spanagel R, Zieglgansberger W (1997). Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18: 54–59.
Stinus L, Caille S, Koob GF (2000). Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology 149: 115–120.
Stinus L, Le Moal M, Koob GF (1990). Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37: 767–773.
Substance Abuse Mental Health Services Administration (2002). Opioid drugs in maintenance and detoxification treatment of opiate addiction: addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Federal Register 68: 27937–27939.
Tzschentke TM (2002). Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 161: 1–16.
Valentino RJ, Foote SL, Page ME (1993). The locus coeruleus as a site for integrating corticotropin-eleasing factor and noradrenergic mediation of stress responses. In: Tache Y, Rivier C (eds). Corticotropin-Releasing Factor and Cytokines: Role in the Stress Response (series title: Annals of the New York Academy of Sciences, Vol. 697). New York Academy of Sciences: New York. pp 173–188.
Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995). Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274: 361–372.
Wikler A (1948). Recent progress in research on the neurophysiologic basis of morphine addiction. Am J Psychiatry 105: 329–338.
Wikler A (1973). Dynamics of drug dependence: implications of a conditioning theory for research and treatment. Arch Gen Psychiatry 28: 611–616.
Wikler A, Pescor FT (1967). Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and ‘relapse’ in morphine-addicted rats. Psychopharmacologia 10: 255–284.
Wong DT, Reid LR, Bymaster FP, Threlkeld PG (1985). Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J Neural Transm 64: 251–269.
Zeise ML, Kasparov S, Capogna M, Zieglgansberger W (1993). Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 231: 47–52.
Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34: 171–181.
Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002). Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188–199.
Acknowledgements
This is publication number 16070-NP from The Scripps Research Institute. This research was supported by National Institutes of Health Grant DA04043 from the National Institute on Drug Abuse (GFK), the University of Bordeaux 2 (LS, MC), the Centre National de le Recherche Scientifique (LS, MC), the Conseil Regional d'Aquitaine (LS, MC), and Merck Lipha (LS and GFK). GFK also has served as a consultant for Merck Lipha. We thank Mike Arends for his help in preparing and editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stinus, L., Cador, M., Zorrilla, E. et al. Buprenorphine and a CRF1 Antagonist Block the Acquisition of Opiate Withdrawal-Induced Conditioned Place Aversion in Rats. Neuropsychopharmacol 30, 90–98 (2005). https://doi.org/10.1038/sj.npp.1300487
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300487
Keywords
This article is cited by
-
Opioid withdrawal: role in addiction and neural mechanisms
Psychopharmacology (2023)
-
Alteration of neuroinflammation detected by 18F-GE180 PET imaging in place-conditioned rats with morphine withdrawal
EJNMMI Research (2021)
-
Comparative benefits of social housing and buprenorphine on wheel running depressed by morphine withdrawal in rats
Psychopharmacology (2021)
-
Opposing mechanisms mediate morphine- and cocaine-induced generation of silent synapses
Nature Neuroscience (2016)
-
Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use
Molecular Psychiatry (2016)
